Cumberland Pharmaceuticals (CPIX) Debt to Equity (2016 - 2025)
Cumberland Pharmaceuticals (CPIX) has disclosed Debt to Equity for 15 consecutive years, with $0.21 as the latest value for Q4 2025.
- Quarterly Debt to Equity fell 68.06% to $0.21 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.21 through Dec 2025, down 68.06% year-over-year, with the annual reading at $0.21 for FY2025, 68.06% down from the prior year.
- Debt to Equity hit $0.21 in Q4 2025 for Cumberland Pharmaceuticals, up from $0.2 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.67 in Q4 2024 to a low of $0.18 in Q1 2025.
- Historically, Debt to Equity has averaged $0.4 across 5 years, with a median of $0.4 in 2023.
- Biggest five-year swings in Debt to Equity: skyrocketed 81.44% in 2024 and later tumbled 69.49% in 2025.
- Year by year, Debt to Equity stood at $0.35 in 2021, then grew by 27.9% to $0.45 in 2022, then dropped by 2.98% to $0.44 in 2023, then skyrocketed by 52.99% to $0.67 in 2024, then crashed by 68.06% to $0.21 in 2025.
- Business Quant data shows Debt to Equity for CPIX at $0.21 in Q4 2025, $0.2 in Q3 2025, and $0.19 in Q2 2025.